DispersinB(R) Efficacy Study Published in the Journal of Antimicrobial Chemotherapy
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 06/08/09 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce its research publication on the Company's patented DispersinB® antibiofilm technology in the latest online edition of the Journal of Antimicrobial Chemotherapy (doi:10.1093/jac/dkp158; Impact Factor: 4.038).
The publication, entitled "Antimicrobial and antibiofilm efficacy of triclosan and DispersinB® combination" authored by Dr. Rabih Darouiche (Darouiche et al.) at Baylor College of Medicine, Houston, Texas, concludes that catheters coated with the combination of DispersinB® and the antimicrobial triclosan showed synergistic, broad-spectrum and durable antimicrobial activity.
"The combination showed synergistic antimicrobial and antibiofilm activity against Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli, and significantly reduced bacterial colonization and generally demonstrated a prolonged superior antimicrobial activity against clinical pathogens when compared with the chlorhexidine and silver-sulfadiazine coated central venous catheters on the market today," stated Dr. Darouiche. "Furthermore, the in-vivo efficacy of catheters coated with this unique antimicrobial/antibiofilm composition prompts clinical evaluation of such an innovative approach".
"This publication on the antimicrobial and antibiofilm efficacy of triclosan in combination with DispersinB® emphasizes the importance of having both the antimicrobial and antibiofilm components in a device coating in order to reduce the risk of device-related infections involving biofilms, which account for over 80% of all hospital-acquired infections," stated Dr. Sri Madhyastha, Chief Scientific Officer of Kane Biotech.
"This is Kane's first DispersinB® antibiofilm enzyme related research publication, which now adds to the growing list of publications on DispersinB® from research labs all over the world," added Dr. Madhyastha.
About Dr. Darouiche
Rabih O. Darouiche, M.D., is the founder and director of the Center for Prostheses Infection. He is a VA Distinguished Service Professor in the Departments of Medicine and Physical Medicine & Rehabilitation at Baylor College of Medicine, and a staff physician in the Medical (Infectious Disease Section) and Spinal Cord Injury Services at the Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. Board Certified in internal medicine, infectious disease, and spinal cord injury medicine. Dr. Darouiche is an outstanding clinician and excellent academician. Additionally, Dr. Darouiche is an internationally renowned researcher with clinically proven approaches for rendering medical devices anti-infective. The author of over 140 articles and textbook chapters, Dr. Darouiche is known for his prominent work in the area of prosthesis infection. His publications, such as the lead article in the New England Journal of Medicine (1999;340:1-8) entitled, "A Comparison of Two Antimicrobial-Impregnated Central Venous Catheters," have had an overwhelming impact on patient care.
About Baylor College
Baylor College of Medicine (BCM) in Houston, Texas was founded in 1900 and is today an internationally respected medical and research institution known for excellence in education, research and patient care. For 2008, U.S. News & World Report again has ranked the college 10th overall among the nation's top medical schools for research and 11th for primary care. BCM is also listed 13th among all U.S. medical schools for National Institutes of Health funding, and No. 1 for research expenditures in biological science by the National Science Foundation. Located in the Texas Medical Center, a 700-acre complex housing 42 member institutions, BCM has affiliations with seven teaching hospitals, each with a national and international reputation for medical excellence. The college has total research support of $374 million, with $314 million from federal sources, and more than 90 research and patient-care centers and units. Currently, BCM trains more than 3,000 medical, graduate, nurse anesthesia, and physician assistant students, as well as residents and post-doctoral fellows.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Kane Biotech Inc. Gord Froehlich President & Chief Executive Officer 204-477-7592 204-453-1314 (FAX) email@example.com www.kanebiotech.com
Released June 8, 2009